Tag: CStone
AACR 2026: Preclinical Advances in Bispecific and Novel ADCs
At the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA., new preclinical data will be presented for three proprietary antibody-drug conjugate (ADC) assets—CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC)—being developed by CStone Pharmaceuticals.
AACR 2025: China is Leading the Way in ADC Development
During AACR 2025 representatives of multiple Chinese biotech companies demonstrating the diversity and cutting-edge advancements innovations in the development of novel antibody-drug conjugates (ADC),
